Targeting PI3K/AKT/mTOR and MAPK pathways by combined PD325901 (MEK inhibitor) and rapamycin (mTOR inhibitor) treatment reduced prostate tumor burden of Nkx3.1+/−Pten+/− mice, particularly following castration [110]. The gene discussed is MTOR; the disease is prostate neoplasm.